Skip to main content
. Author manuscript; available in PMC: 2019 Apr 15.
Published in final edited form as: Int J Cancer. 2017 Dec 15;142(8):1652–1663. doi: 10.1002/ijc.31196

Figure 4. A small molecular inhibitor of Ezrin inhibits the growth and metastasis of melanoma cells.

Figure 4

(a) Western blot analysis of B16F1-HGF/Met cells treated with the Ezrin inhibitor NSC668394 for 2 hours with the indicated dosage. (b) The relative cell proliferation of B16F1-HGF/Met melanoma cells treated with the indicated dose of the Ezrin inhibitor NSC668394 for 24 hours. (c, d) Tumor growth curve (c) and tumor weight (d) of B16F1-HGF/Met cells in xenograft syngeneic C57/BL6-c-Brd mice with (Inh Ez, n=10)/without (Mock, n=10) treatment of Ezrin inhibitor NSC668394. (e) Gross pulmonary metastases in B16F1-HGF/Met cells from syngeneic C57/BL6-c-Brd mice treated with Ezrin inhibitor NSC668394 (Inh Ez, n=10) and control (Mock, n=10). (f) Representation of lung H&E staining of metastases of B16F1-HGF/Met cells in syngeneic C57/BL6-c-Brd mice treated with the Ezrin inhibitor (Inh Ez) or PBS (Mock). (g) Number of macro- and micro- metastases of B16F1-HGF/Met cells in syngeneic C57/BL6-c-Brd mice treated with the Ezrin inhibitor (Inh Ez, n=6) or control (Mock, n=6) in lung sections.